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Original Article 
A B S T R A C T 
Background:   Despite several rounds of Mass Drug Administration (MDA) as an elimination strategy of Lymphatic 
Filariasis (LF) from India, still the coverage is far behind the required level of 85%.  
 
Objectives:   The present study was carried out with the objectives to assess the coverage and compliance of MDA 
and their possible determinants.  
 
Methods:  A cross-sectional community based study was conducted in Paschim Midnapur district of West Bengal, 
India for consecutive two years following MDA. Study participants were chosen by 30-cluster sampling technique. 
Data was collected by using pre-tested semi-structured proforma to assess the coverage and compliance of MDA 
along with possible determinants for non-attaining the expected coverage.    
 
Results:   In the year 2009, coverage, compliance, coverage compliance gap (CCG) and effective coverage was seen 
to be 84.1%, 70.5%, 29.5% and 59.3% respectively. In 2010, the results further deteriorated to 78.5%, 66.9%, 33.3% 
and 57% respectively. The poor coverage and compliance were attributed to improper training of service providers 
and lack of community awareness regarding MDA.  
 
Conclusion: The study emphasized supervised consumption, retraining of service providers before MDA activities, 
strengthening  behaviour  change  communication  strategy  for  community  awareness.  Advocacy  by  the  program 
managers and policy makers towards prioritization of MDA program will make the story of filaria elimination a 
success.  
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Introduction: 
Several decades of research and the availability of new 
diagnostic and effective control tools have led to the 
development  of  a  strategy  to  eliminate  Lymphatic 
Filariasis.  The  newer  strategy  for  elimination  of 
Lymphatic  Filariasis  aims  at  breaking  the  chain  of 
transmission  through  annual  single-dose  Mass  Drug 
Administration  (MDA)  which    reduces  blood 
microfilaria  by  99%  while  two  drugs  [Ivermectin  + 
Diethyl  Carbamazine  Citrate  (DEC)  or  Albendazole]  
co-administered  and  90%  when    single  drug 
(Ivermectin  or    DEC)    used.
1  Accordingly,  India’s 
National  Vector  Borne  Disease  Control  Program  had 
scaled-up  mass  drug  administration  (MDA)  strategy 
nationwide  through  administration  of  single  dose  of 
DEC by observing “National filarial Day” (NFD) since 
2004.  A  high  coverage  of  MDA  (>85%)  in  endemic 
areas  sustained  for  consecutive  five  years  is  the  
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prerequisite  for  the  interruption  of  transmission  and 
elimination of Filariasis in India.
2  
 Despite several rounds of MDA, still the coverage and 
compliance  are  far  behind  the  required  coverage  as 
reported by several studies in few states of India viz. 
Orissa and Andhra Pradesh.
3 West Bengal, another state 
of India was also implementing MDA since 2004 and 
coverage had gradually increased from 39.58% in 2004 
to  77.79%  in  2008.  Though  microfilaria  rate  was 
reported as zero for consecutive two years in Paschim 
Midnapur  district,  a  study  from  adjacent  district 
revealed microfilaria rate as 9.06%, mean microfilaria 
density 8.63% and disease rate as 7.72%. 
4, 5 
Keeping  these  facts  in  mind,  Government  of  West 
Bengal had decided to evaluate district wise coverage 
and  compliance  of  MDA  along  with  extent  of 
Information  Education  and  Communication  (IEC) 
activities.  Department  of  Community  Medicine  of 
Midnapur  Medical  College  was  entrusted  to  evaluate 
the situation in the district of Paschim Midnapur.  
The study hypothesis was whether effective coverage of 
MDA  was  thought  to  be  sufficient  to  achieve  the 
elimination  level  of  LF  in  the  district  of  Paschim 
Midnapur of West Bengal? The main challenge of the 
study was to find out the outcomes of MDA programme 
with  an  aim  to  overcome  the  possible  bottlenecks  in 
future  for  success  in  elimination  of  Lymphatic 
Filariasis.     
The objectives of the study were to assess the coverage 
and compliance of Mass Drug Administration (MDA) 
and possible reasons for noncompliance; to document 
the  side  effects  of  MDA  if  any  and  to  assess  the 
knowledge  of  the  community  regarding  Lymphatic 
Filariasis and MDA.  
Methods  
Study Setting and Study Design: The largest district 
of West Bengal, Paschim Midnapur is situated 139 km 
away from Kolkata with a population of 5.94 million 
with tribal predominance.  The district is noted for its 
great geographical diversity.  The district experienced 
insufficient both public and private health care delivery 
system.
6 A cross-sectional descriptive community based 
study  had  been  conducted  consecutively  in  2009  and 
2010  in  the  district  of  Paschim  Midnapur  of  West 
Bengal, India. The present study was conducted in two 
phases.  The  first  phase  comprised  of  quantitative 
survey.  The  second  phase  comprised  of  post-survey 
qualitative  study  (mainly  FGDs:  Focus  Group 
Discussions)  to  bridge  the  identified  gaps  in  the 
information  gathered  from  the  survey  and  also  to 
identify the possible obstacles for achieving the desired 
coverage  along  with  possible  reasons  for  non-
compliance.
7  
 
Sample Size and Sampling Method: Considering the 
previous  MDA  coverage  of  77.8%  in  West  Bengal,
8  
5% alpha error; 5% absolute precision and design effect 
of 2; the minimum required sample size was estimated 
526.  Considering  the  5%  non-response  rate,  the  final 
sample size estimated to be 553.
9 Multi-stage 30-cluster 
sampling technique was used for selection of the study 
participants.
10  According  to  the  reported  coverage  of 
previous MDA activities by the district health authority, 
three  areas;  one  from  each  chosen  randomly  as  the 
study units from the list of high (> 80% coverage of 
MDA),  medium  (50-80%  MDA  coverage)  and  low 
coverage  (<  50%  MDA  coverage)  areas  by  simple 
random  sampling  to  ensure  equal  representation.  The 
study  sample  was  drawn  from  the  three  different 
reported  coverage  areas  by  30-cluster  sampling 
technique,  where  the  number  of  clusters  was 
proportional to the population. From each cluster, 19 
study  participants  were  chosen  by  systematic 
randomization.  A  total  630  and  754  population  were 
covered in 2009 and 2010 respectively.   
 
Ethical  Issues:  The  study  was  approved  by  the 
Institutional  Ethical  Committee  of  Midnapur  Medical 
College and informed written consent obtained from the 
each respondent prior to the data collection. 
 
Data  Collection:  The  head  of  the  household  or  any 
responsible  adult  member  was  considered  as  the 
respondent.  Prior  information  was  given  to  some 
responsible  community  leaders  for  sustained  co-
operation.    A  group  of  trained  interviewers  collected 
data  by  using  a  pre-tested  semi-structured  proforma 
undertaking house-to-house visits within two weeks of 
the MDA campaign over a period of seven days in both 
the  years.    The  whole  activities  were  supervised  and 
20% of the proforma were cross-checked on the field 
by  the  trained  faculty  members  of  the  department  of 
community  medicine. Data editing and cleaning were 
done by trained data manager before data entry. Quality 
control  measures  were  taken  in  each  stage  of  data 
collection,  collation,  compilation  and  analysis. 
Information collected on  number of eligible members 
in  the  family;  coverage  and  consumption  of  MDA; 
possible  reasons  for  not  consumption;  side  effects,  if 
any;  perception  of  the  respondent  about  Lymphatic 
Filariasis & MDA and sources of knowledge. Eligible 
persons in the family were determined by excluding the 
children  less  than  2  years,  pregnant  women  and 
severely ill persons from the family members. Correct 
dose  received  was  determined  who  received  the 
recommended DEC dosage i.e one tablet (100 mg) to 
children  of  age  2-5  yr,  two  tablets  for  6-14  yr  age 
group, and three tablets for those > 14 yrs of age.   
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A total six focus group discussions (FGDs) both with 
the  health  care  providers  as  well  as  with    the 
responsible community members (Two in each of the 
three  reported  coverage  areas;  one  with  health  care 
providers  and  other  with  responsible  community 
members) were also carried out to find out the possible 
obstacles  for  desired  coverage  and  reasons  for  non-
compliance. After obtaining informed consent, a group 
of  trained  faculty  members  from  the  department  of 
Community Medicine, Midnapur Medical College, and 
West  Bengal  facilitated  FGDs  following  structured 
guidelines  in  local  Bengali  language  and  a  recorder 
carefully recorded the discussions.    
 
The  main  evaluation  criteria  for  the  study  were  to 
assess  the  coverage  and  compliance  of  MDA 
programme and possible correlates for noncompliance 
along  with  the  impact  of  BCC  (Behavioral  Change 
communication) strategies delivered by the government 
for successful implementation of the MDA programme.  
 
Statistical Analysis: 
The data was analyzed by using Epi_info 6.04 software 
package.    Simple  proportions  were  used  for 
interpretation and expressed as coverage, compliance, 
effective  coverage  (EC:  proportion  of  compliance  in 
respect to eligible population) and coverage compliance 
gap (CCG: proportion of covered people not consuming 
the drugs). Z tests were used for comparisons between 
two proportions and P < 0.05 was taken as the level of 
significance. A content analysis of the qualitative data 
was undertaken. 
Results  
A total 630 and 754 population was covered in 2009 
and  2010  by  undertaken  survey  among  131  and  135 
households respectively in Paschim Midnapur district. 
Total  592  and  659  eligible  populations  were  found 
respectively  in  the  two  successive  years  respectively. 
Males and females were of almost equally distributed in 
both  the  years.  According  to  age  groups,  7.1%  and 
5.5% belonged to 2-5 years, 16.6% and 18.6% to 6-14 
years and 76.3% and 75.9% above 14 years in 2009 and 
2010  respectively.  Majority  of  the  respondents  were 
above 18 years and females in both the years with the 
median age of 34 and 35 respectively. 
 
In  the  year  2009,  84.1%  eligible  members  received 
DEC  and  among  those  who  received  DEC,  70.5% 
consumed  with a coverage compliance gap of  29.5% 
and effective coverage being 59.3% [Table 1]. In the 
year 2009, among 29.5% who had not complied, 15.9% 
had not received the drugs and remaining 13.6% had 
not  consumed  them  [Figure  1].  Distribution  of 
Albendazole tablets was not included in the program in 
that year.  In 2010, 78.5% received DEC and among 
those  received,  66.9%  consumed  DEC  with  the 
coverage-compliance gap and effective coverage were 
33.3% and 57% respectively.  In 2010, a total of 33.3% 
of  the  respondents  had  not  complied  MDA,  out  of 
which 21.5% had not received the drugs and 11.8% did 
not  consume  [Figure  1].  In  that  year  76.9%  received 
Albendazole tablets, of which 65.1% consumed them. 
The  difference  of  coverage  and  compliance  of  MDA 
between  2009  and  2010  were  seen  statistically 
significant  (Coverage:  z=  11.25,  p=  0.008  and 
Compliance:  z=  14.00,  p=  0.007).  The  data  was 
calculated based on correct doses of DEC received and 
correct  doses  consumed.  While  considering  the  age 
wise  compliance  of  MDA  in  2009  and  2010, 
compliance  was  also  significantly  less  in  2-  5  years 
(71.4%  vs.  58.6%, p=0.006)  and  above  14  years  age 
groups (70.6% vs. 66.2%, p= 0.006) in 2010 compared 
to  2009.  While  comparing  sex  and  residence  wise, 
compliance was also significantly lower in both sexes 
(p=  0.006)  and  both  rural  and  urban  population  (p= 
0.006)  in  2010  compared  to  2009  [Table  1].  
 
 
 
Table 1: Coverage compliance gap (CCG) and Effective coverage (EC) according to 
Selected demographic characteristics 
 
Demographic   
Characteristic 
2009  2010 
Eligible 
popln. 
 
(n=592) 
Cover 
age 
(n=498) 
Compli 
ance 
(n=351) 
CCG
* 
(%) 
EC** 
 
(%) 
Eligible 
popln. 
 
(n=754) 
Cover 
age 
(n=717) 
Compli 
ance 
(n=377) 
CCG
* 
(%) 
EC** 
 
(%) 
Age (Years) : 
           2 - 5 
           6 - 14 
           >14 
 
42  
98 
412 
 
35 
82 
381 
 
25 
57 
269 
 
28.6 
30.5 
29.4 
 
59.5 
58.2 
59.5 
 
37 
122 
500 
 
29 
90 
444 
 
17 
65 
294 
 
41.4 
27.8 
33.8 
 
45.9 
50.2 
61.4 
Sex:                      
Global J of Medicine and Public Health (www.gjmedph.org) /Jan-Feb / Vol 1(1)  Page 6 
 
          Male 
          Female 
289 
303 
243 
255 
170 
181 
30.0 
29.0 
58.8 
59.7 
328 
331 
287 
276 
191 
185 
33.4 
33.0 
58.2 
55.9 
Residence: 
         Rural 
        Urban 
 
429 
163 
 
360 
138 
 
259 
99 
 
30.0 
28.3 
 
58.7 
60.7 
 
498 
161 
 
428 
135 
 
285 
91 
 
33.4 
32.6 
 
57.2 
56.5 
Total   592  498  351  29.5  59.3  754  717  377  33.3  57.0 
* CCG: Coverage Compliance gap;      ** EC: Effective Coverage 
 
In  2010,  drugs  were  distributed  by  community 
volunteers  (48.8%),  Auxiliary  Nurse  Mid-wives  i.e. 
ANMs (34.4%), followed by Anganwadi Workers i.e. 
AWWs (6.4%) and Accredited Social Health Activists 
i.e.  ASHAs  (5.4%).  But  in  no  case,  it  was  found 
supervised. In 2009, drugs were mainly distributed by 
ANMs and local volunteers, but no workers persuaded 
the defaulters to take drugs and no persons swallowed 
drugs in front of the workers as they were instructed to 
take the tablets after meals. 
 
Fear of side effects was the most frequent cause of non-
consumption of DEC in both the years -  69.4% (102 
out  of  147)  in  2009  and  72.6%  (135  out  of  186)  in 
2010, followed by unawareness and lack of faith. In 11 
households, 24 (5.7%) persons had side effects in 2010, 
of which 21 i.e 87.9% had dizziness. Other side effects 
were  fever  and  vomiting.  All  these  side  effects  were 
reported from only one rural block. Most of the side 
effects occurred within 24 hours (95.8%), out of which 
45.8% of the side effects were reported to occur within 
one hour of consuming the drugs. Although 79% didn’t 
consult, 16.4% consulted ANM for side effects. No side 
effects were reported in 2009. 
 
Among  the  respondents,  the  knowledge  about 
lymphatic Filariasis, symptoms, mosquito as important 
element behind filaria and anti mosquito and MDA as 
preventive measures were significantly lower in 2010 
than  2009,  but  knowledge  about  MDA  was  seen 
significantly better in 2010 compared to 2009 [Table 2]. 
Regarding  symptoms  of  filaria,  majority  perceived 
swelling of legs (>95%) and fever (about 45%) as the 
symptoms. While assessing the source of information, 
in  2010,  majority  got  the  information  from  ANM 
(66.7%)  followed  by  relatives  and  ASHA.  Regarding 
the  communication  channels,  33.3%  received  the 
information  through  Inter  Personal  Communication 
followed by 15% from television. 97% respondents told 
that health workers didn’t talk with them about MDA in 
last fortnight. In 2009, 64.9% of the respondents heard 
first  time  about  MDA  on  the  day  of  drug 
administration; 76.3% were explained about the disease 
and its transmission and only 28.2% could know about 
MDA from miking and hand bills.  
 
Table 2: Knowledge regarding Lymphatic Filariasis and MDA programme 
Knowledge  2009  
  No.        (%) 
2010 
  No.           (%) 
p value 
Heard about  L.F  83/131   (63.4)  78/135      (57.8)  0.006 
Correctly told 1or 2 symptoms  64/83     (77.1)  54/78        (69.2)  0.007 
Mode of transmission of L.F : 
Mosquito 
Wrong/ no knowledge 
 
41/83     (49.4) 
42/83     (50.6) 
 
32/78        (41.0) 
46/78        (59.0) 
 
0.0045 
0.0047 
Disease can be prevented  41/83    (49.4)  35/78       (44.9)  0.005 
Modes of prevention* : 
        Anti-mosquito measures 
        M.D.A 
        Wrong or No knowledge 
 
20/41     (48.1) 
07/41     (17.1) 
16/41     (39.0) 
 
20/35        (58.4) 
08/35        (22.8) 
16/35        (45.7) 
 
0.005 
0.001 
Heard about M.D.A  54/131(41.2)  60/135(44.4)  0.004 
    * Multiple responses 
Focus  group  discussion  of  the  health  care  providers 
revealed  that  in  many  cases  drugs  could  not  be 
distributed to the beneficiaries as the family was out of 
station  on  the  ‘Filaria’  day,  shortage  of  drugs  or 
manpower, lack of interest among drug distributers due 
to  poor  incentive.  It  was  also  evident  that  the  health  
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care providers had misconception about eligibility and 
correct  doses  of  MDA  for  different  age  groups.  The 
reasons for non- compliance as revealed from in depth 
interview  of  community  members  were  drug 
distributors  not  visiting  the  households,  lack  of 
confidence  upon  some  drug  distributors,  people  not 
feeling the necessity for consumption of MDA as they 
were healthy or did not have any symptoms, forget to 
consume, too many tablets to be taken at a time, fear of 
side  effects  especially  in  case  of  children  and  poor 
awareness regarding the benefits of MDA. 
 
Discussion Lymphatic Filariasis (LF) is a major public 
health problem in India.  The disease remains a major 
impediment  to  socio-economic  development  the 
country. 
The present  study revealed  MDA coverage of 84.1% 
and 78.5% in 2009 and 2010 respectively in the studied 
areas of Paschim Midnapur district, which was less than 
the national coverage as well as the desired coverage 
level for elimination of Lymphatic Filariasis.
2 Similar 
coverage  was  reported  by  two  other  studies  from 
India.
11,12  Several    studies  across  the  India  reported 
even lower coverage ranged from 32.7% to 76.2%.
3, 13-
15 Though a study from Sri Lanka also reported a more 
or  less  similar  (79.6%)  coverage,  lesser    coverage 
(58%) reported from Indonesia.
16,17 
 
The  success  of  elimination  mainly  depends  on  the 
actual  consumption  or  compliance  with  MDA  rather 
than the MDA coverage. Published estimates reporting 
MDA  coverage  often  overestimated  the  actual 
consumption.
18, 19  
 
The  present  study  revealed  that  actual  MDA 
compliance  was 70.5% and 66.9% in 2009 and 2010 
respectively  which  corroborates  with  the  findings  of 
few other studies.
3,13,16  But, several other studies across 
India  revealed  varied  MDA  compliance  ranged  from 
42% to 89%. 
11,12,14,15 
 
 
 
Coverage compliance gap (CCG) is a better indicator 
for assessing the effectiveness of MDA program among 
programme managers. It actually reflects the proportion 
of  covered  people  not  consuming  the  drugs  and 
explores  the  possible  determinants  for  non-
consumption.  The  present  study  revealed  a  CCG  of 
29.5% and 33.3% in 2009 and 2010 respectively. No 
significant differences in CCG were observed in respect 
to gender, area of residence  and age except in 2010, 
where  CCG  was  found  significantly  more  in  the  age 
group of 2-5 years, probably due to fear of side effects 
among children.   Surprisingly, even 3.8% increase of 
CCG in 2010 was probably due to lesser IEC activities 
in  that  year  as  compared  to  previous  year  (2009)  as 
reflected from our study findings. Lesser proportion of 
CCG  (11%)  was  reported  from  a  study  conducted  in 
Gujrat.
12 The difference might be due to different study 
setting.  The  CCG  may  be  bridged  up  by  giving 
enormous  effort  on  BCC  strategies  to  an  aim  to 
motivate the people for drug consumption and stressed 
on supervised dosage.   
 
Effective  coverage  is  one  of  the  most  valuable 
indicators  because  it  reflects  both  coverage  and 
compliance.  It actually denotes the compliance by the  
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community in respect to the eligible population.  The 
effective  coverage  of  MDA  in  successive  two  years 
(57% and 59.3% in 2009 and 2010 respectively) were 
far  behind  the  recommended  level  (≥85%)  in  the 
present  study.  Here  also,  the  observed  effective 
coverage (EC) found less in 2010. Some studies from 
India  though  reported  better  effective  coverage  of 
MDA, but still not up to the desired level.
12,3,15  
 
From  the  focus  group  discussion  of  the  health  care 
providers and in depth interview of the beneficiaries, it 
was evident that the poor coverage was either due to 
drug  distributors  not  visiting  the  households  or  the 
family  was  out  of  station  on  the  date  of  drug 
distribution.  Desired  coverage  could  not  be  achieved 
due  to  shortage  of  drugs  or  manpower  for  drug 
distribution, lack of adequate monetary incentives and 
the only one day time limit for the distribution of MDA. 
Lack  of  proper  knowledge  regarding  eligibility, 
misclassification  of  the  eligible  population  and 
distribution of incorrect dosage of drugs by some drug 
distributors ultimately affected the coverage as reflected 
from  the  present  study.  Kumar  et  al.  had  similar 
observations in Gujrat.
12 It warrants the proper selection 
of the drug distributors, periodic retraining of them with 
emphasis  on  communication  skills  and  correct 
knowledge regarding LF and MDA including its side 
effects. In this regard, Nandha et al. recommended that 
Anganwari workers (AWWs) could be a better service 
provider/distributor  to  achieve  the  optimal  level  of 
coverage  of  MDA  if  they  could  be  equipped  with 
current  knowledge  and  skills.
11  It  is  also  crucial  to 
monitor  the  quality  of  the  performance  of  grass  root 
level health care providers on a regular basis.   
 
Reported side effects (only 5.7% in 2010 and none in 
2009) after consumption of DEC were found minimal 
in the present study and all of them were mild in nature, 
which indicated low endemicity of filaria in the study 
district.  The  finding  corroborated  with  the  prevailing 
data  from  the  government  of  West  Bengal.
8  Similar 
lower  incidences  of  side  effects  were  reported  from 
endemic  areas  of  Gujrat  and  rural  West  Bengal  of 
India.
12, 20 
 
For  the  compliance  of  MDA,  awareness  of  the 
community  is an important issue. The study revealed 
poor  knowledge  of  the  community  regarding 
“Lymphatic  Filariasis”  and  annual  “Mass  drug 
administration”  (MDA)  even  after  six  rounds  of  the 
MDA program.  Only around 1/5
th of the respondents 
knew  that  MDA  was  an  important  tool  for  the 
prevention of LF and 3/5
th of them had not even heard 
the name of MDA. A great number of respondents told 
that they heard first time about MDA on the day of drug 
distribution.  In  the  years  (2009  and  2010),  the 
knowledge  regarding  LF  and  MDA  were  found 
unsatisfactory and the picture further worsened in 2010. 
Mukhopadhyay  et  al.  also  demonstrated  similar 
observations  in  from  rural  areas  of  Andhra  Pradesh, 
India.
3  Regarding  the  channels  of  behavioral  change 
communication,  both  inter-personal  and  mass  media 
communication  strategy  were  found  inadequate  for 
awareness  generation  among  the  community,  which 
necessitates the strengthening of BCC activities.  The 
success of elimination would not be possible without 
the  generation  of  felt  need  of  the  community/people, 
which must not be ignored.  
 
Reasons for the failure of compliance as evident from 
the present study were people not feeling the necessity 
for consumption because they were healthy or did not 
have  any  symptoms,  forget  to  consume,  too  many 
tablets  to  be  taken  at  a  time,  fear  of  side  effects 
especially in case of children, poor awareness regarding 
the benefits of MDA and lack of confidence upon the 
drug distributors. The present study revealed that drug 
distributors  neither  sensitized  the  community  well  in 
advance regarding the importance of the “Mass Drug 
Administration”  nor  the  conducted  MDA  activities 
were found supervised in both the years. A study from 
Gujrat,  India  also  reported  similar  observations.
12 
Basically the MDA program was found only restricted 
to the distribution of DEC and Albendazole tablets and 
issues like adherence to the drug schedule, knowledge 
of the community regarding Lymphatic Filariasis and 
it’s common preventive and control measures including 
MDA  and  also  the  fear  of  side  effects  were  not 
comprehensively  addressed  as  evidenced  from  this 
study.  Similar findings were observed by several other 
studies across India.
  19,21 In-spite of remarkable social 
burden  and  amenable  for  eradication,  Lymphatic 
Filariasis has not got priority from the policy makers 
and  program  managers  and  thus  making  the  success 
story of elimination a remote possibility. There is ample 
scope  for  advocacy  especially  from  the  public  health 
personals for transforming this issue as a public health 
agenda 
 
Conclusions 
Desired coverage level of MDA which is necessary for 
elimination of lymphatic filariasis was not observed in 
the  present  study  in-spite  of  several  rounds  of  MDA 
activities  since  2004  in  the  district  of  Paschim 
Midnapur. From the programme point of view, the two 
important  outcome  indicators  such  as  coverage 
compliance  gap  (CCG)  and  effective  coverage  (EC) 
which actually reflects the effectiveness of the MDA 
activities were also not up to the recommended level. 
The indicators rather detoriated with passage of time as 
evidenced  from  the  study  which  necessitates  the 
importance of supervised DEC consumption, retraining  
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of  service  providers  before  MDA  activities, 
strengthening  behaviour  change  communication 
strategy  for  community  awareness.  The  community 
should be sensitized and boostered repeatedly though-
out the year by means of inter-personal communication 
by motivated front line health workers as well as mass 
media  communication  strategy  regarding  the  LF  and 
MDA. Advocacy by the program managers and policy 
makers  towards  prioritization  of  MDA  program  will 
make the story of filaria elimination a success.  
However, the limitation of the study should be kept in 
mind. The study was carried out in a small geographical 
area  (in  a  district  of  West  Bengal),  and  the  findings 
should be validated by carrying out large scale studies 
involving large geographical areas so that the findings 
can be generalized to larger population group.   
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